ProQR Therapeutics BV Market Cap ($186.28 Million)
Market Cap & Net Worth: ProQR Therapeutics BV (PRQR)
ProQR Therapeutics BV market cap. ProQR Therapeutics BV (NASDAQ:PRQR) has a market capitalization of $186.28 Million ($186.28 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #16623 globally and #3960 in its home market, demonstrating a 2.33% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ProQR Therapeutics BV's stock price $1.32 by its total outstanding shares 141119032 (141.12 Million). Also see ProQR Therapeutics BV cash flow conversion for how efficiently the company converts equity into cash flow.
ProQR Therapeutics BV Market Cap History (2015–2026)
ProQR Therapeutics BV market cap history from 2015 to 2026. Data shows change from $1.22 Billion to $186.28 Million (-18.75% CAGR). Check current stock price of ProQR Therapeutics BV for real-time trading data and today's change.
Index Memberships
ProQR Therapeutics BV is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.60 Trillion | 0.01% | #450 of 976 |
|
NASDAQ Composite
IXIC
|
$39.84 Trillion | 0.00% | #1632 of 3165 |
Weight: ProQR Therapeutics BV's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
ProQR Therapeutics BV Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ProQR Therapeutics BV's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset momentum of ProQR Therapeutics BV to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
18.66x
ProQR Therapeutics BV's market cap is 18.66 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $691.48 Million | $2.28 Million | -$39.10 Million | 303.02x | N/A |
| 2017 | $455.11 Million | $-1.53 Million | -$43.64 Million | -297.65x | N/A |
| 2018 | $2.23 Billion | $4.94 Million | -$36.89 Million | 450.69x | N/A |
| 2019 | $1.40 Billion | $1.93 Million | -$56.75 Million | 723.48x | N/A |
| 2020 | $592.70 Million | $1.03 Million | -$46.56 Million | 576.00x | N/A |
| 2021 | $1.13 Billion | $1.33 Million | -$60.74 Million | 846.71x | N/A |
| 2022 | $522.14 Million | $3.59 Million | -$64.42 Million | 145.28x | N/A |
| 2023 | $279.42 Million | $6.51 Million | -$28.12 Million | 42.89x | N/A |
| 2024 | $373.97 Million | $18.91 Million | -$27.76 Million | 19.78x | N/A |
| 2025 | $285.06 Million | $15.28 Million | -$40.52 Million | 18.66x | N/A |
Competitor Companies of PRQR by Market Capitalization
Companies near ProQR Therapeutics BV in the global market cap rankings as of November 4, 2026. Also see balance sheet size of ProQR Therapeutics BV for a full breakdown of the balance sheet.
Key companies related to ProQR Therapeutics BV by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #372 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #411 globally with a market cap of $69.05 Billion USD ( AU$97.59 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #497 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $553.15 |
| #372 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $961.26 |
| #411 | CSL Ltd | AU:CSL | $69.05 Billion | AU$201.16 |
| #497 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $220.83 |
Market Capitalization of ProQR Therapeutics BV (2015–2026)
Market capitalization of ProQR Therapeutics BV from 2015 to today. Between 2015 and today, ProQR Therapeutics BV's market cap moved from $1.22 Billion to $ 186.28 Million, with a yearly change of -18.75%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $186.28 Million | -34.65% |
| 2025 | $285.06 Million | -23.77% |
| 2024 | $373.97 Million | +33.84% |
| 2023 | $279.42 Million | -46.49% |
| 2022 | $522.14 Million | -53.81% |
| 2021 | $1.13 Billion | +90.71% |
| 2020 | $592.70 Million | -57.62% |
| 2019 | $1.40 Billion | -37.20% |
| 2018 | $2.23 Billion | +389.30% |
| 2017 | $455.11 Million | -34.18% |
| 2016 | $691.48 Million | -43.55% |
| 2015 | $1.22 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of ProQR Therapeutics BV was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $186.28 Million USD |
| MoneyControl | $186.28 Million USD |
| MarketWatch | $186.28 Million USD |
| marketcap.company | $186.28 Million USD |
| Reuters | $186.28 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About ProQR Therapeutics BV
ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs. Its lead product candidate, AX-0810, targets na-taurocholate cotransporting polypeptide (NTCP) for the treatment of cholestatic disea… Read more